Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 14/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 12/20 | 0.67 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8287007 | 0.88 | PTGS1 (0.65) | PTGS1PTGS2POLB | |
| SCHEMBL8289158 | 0.88 | PTGS1 (0.64) | PTGS1PTGS2POLBTDP1 | |
| SCHEMBL8302475 | 0.87 | PTGS1 (0.71) | PTGS1PTGS2HTR2CHTR2BP2RX7 | |
| SCHEMBL14516244 | 0.85 | PTGS1 (0.79) | PTGS1PTGS2 | |
| SCHEMBL14497487 | 0.84 | PTGS1 (0.77) | PTGS1PTGS2POLBTDP1 | |
| SCHEMBL8289162 | 0.81 | PTGS1 (0.60) | PTGS1PTGS2P2RX7 | |
| SCHEMBL8289145 | 0.80 | PTGS1 (0.55) | PTGS1PTGS2P2RX7POLB | |
| SCHEMBL8289146 | 0.80 | PTGS1 (0.67) | PTGS1PTGS2POLB | |
| SCHEMBL8289159 | 0.78 | PTGS1 (0.57) | PTGS1PTGS2POLB | |
| SCHEMBL8287003 | 0.78 | PTGS1 (0.62) | PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005046615-A2 | COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM MEDIATED DISORDERS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005037193-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR ADMINISTERED UNDER HYPOTHERMIC CONDITIONS FOR THE TREATMENT OF ISCHEMIC MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005018569-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SEROTONIN MODULATING AGENT FOR THE TREATMENT OF NEOPLASIA | PHARMACIA CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005009354-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN IKK INHIBITOR FOR THE TREATMENT OF ISCHEMIC-MEDIATED CENTRAL NERVOUS SYSTEM DISORDERS OR INJURY | PHARMACIA CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005007156-A1 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND AN ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2005007106-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A NON-NMDA GLUTAMATE MODULATOR FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| WO-2004093816-A2 | COMPOSITIONS COMPRISING A SELECTIVE COX-2 INHIBITOR AND A CALCIUM MODULATING AGENT | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004093814-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM CHANNEL BLOCKER | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |